Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin h

  • ACS Med Chem Lett. 2012 Sep 7;3(10):814-7. doi: 10.1021/ml300173e.
Sheo B Singh  1 Weiguo Liu  1 Xiaohua Li  1 Tom Chen  1 Ali Shafiee  1 Deborah Card  1 George Abruzzo  1 Amy Flattery  1 Charles Gill  1 John R Thompson  1 Mark Rosenbach  1 Sarah Dreikorn  1 Viktor Hornak  1 Maria Meinz  1 Myra Kurtz  1 Rosemarie Kelly  1 Janet C Onishi  1
Affiliations
  • 1. Departments Medicinal Chemistry and Infectious Diseases, Merck Research Laboratories , Rahway, New Jersey 07065, United States.
Abstract

Ilicicolin H is a polyketide-nonribosomal peptide synthase (NRPS)-natural product isolated from Gliocadium roseum, which exhibits potent and broad spectrum Antifungal activity, with sub-μg/mL MICs against Candida spp., Aspergillus fumigatus, and Cryptococcus spp. It showed a novel mode of action, potent inhibition (IC50 = 2-3 ng/mL) of the mitochondrial cytochrome bc1 reductase, and over 1000-fold selectivity relative to rat liver cytochrome bc1 reductase. Ilicicolin H exhibited in vivo efficacy in murine models of Candida albicans and Cryptococcus neoformans infections, but efficacy may have been limited by high plasma protein binding. Systematic structural modification of ilicicolin H was undertaken to understand the structural requirement for the Antifungal activity. The details of the biological activity of ilicicolin H and structural modification of some of the key parts of the molecule and resulting activity of the derivatives are discussed. These data suggest that the β-keto group is critical for the Antifungal activity.

Keywords
Gliocadium roseum; antifungal activity; broad spectrum; cytochrome bc1 reductase inhibitor; ilicicolin H; in vivo efficacy.
Products